To recruit Clinical Laboratory Improvements Program (CLIA) accredited laboratories to participate in NCI-ComboMATCH, the National Cancer Institute (NCI) published two solicitations in the Federal Register, effective March 11, 2020. The solicitations were for laboratories that test tumor specimens from patients utilizing next-generation sequencing (NGS) assays:

When this trial opens, the recruited laboratories (to be announced) will identify patients who have the specific gene abnormalities needed for trial eligibility using assays they perform as standard-of-care. Laboratories will contact physicians at participating clinical sites if a specimen they send for testing has a gene abnormality that would potentially make the patient eligible for one of the treatment arms.